Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Share-based Compensation (2020 - 2025)

Ovid Therapeutics' Share-based Compensation history spans 6 years, with the latest figure at $1.2 million for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 5.16% year-over-year to $1.2 million; the TTM value through Dec 2025 reached $4.8 million, down 23.41%, while the annual FY2025 figure was $4.8 million, 23.41% down from the prior year.
  • Share-based Compensation reached $1.2 million in Q4 2025 per OVID's latest filing, up from $1.1 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $2.0 million in Q1 2024 to a low of $1.1 million in Q3 2025.
  • Average Share-based Compensation over 5 years is $1.5 million, with a median of $1.3 million recorded in 2021.
  • Peak YoY movement for Share-based Compensation: tumbled 55.59% in 2021, then surged 53.37% in 2022.
  • A 5-year view of Share-based Compensation shows it stood at $1.3 million in 2021, then surged by 31.51% to $1.7 million in 2022, then rose by 3.43% to $1.8 million in 2023, then decreased by 29.57% to $1.3 million in 2024, then decreased by 5.16% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for OVID's Share-based Compensation are $1.2 million (Q4 2025), $1.1 million (Q3 2025), and $1.2 million (Q2 2025).